Reflux patterns in patients with short-segment Barrett's oesophagus: a study using impedance-pH monitoring off and on proton pump inhibitor therapy

Aliment Pharmacol Ther. 2009 Sep 1;30(5):508-15. doi: 10.1111/j.1365-2036.2009.04063.x. Epub 2009 Jun 10.

Abstract

Background: In short-segment Barrett's oesophagus (SSBO) heartburn may be absent and oesophageal acid exposure time (OAET) assessed with pH-only monitoring may be normal. By detecting reflux episodes independently of their acidity, multichannel intraluminal impedance-pH (MII-pH) monitoring allows a comprehensive characterization of reflux events, either off or on proton pump inhibitor (PPI) therapy.

Aim: To assess reflux parameters by MII-pH monitoring in newly diagnosed SSBO, at baseline and as modified with PPI therapy.

Methods: Short-segment Barrett's oesophagus was defined by oesophageal intestinal metaplasia up to 3 cm in length. 24-h MII-pH monitoring was performed before and during PPI therapy.

Results: Fifty patients were studied prospectively. Normal OAET was found at baseline in 15 patients (30%), 8 and 2 of whom with a higher than normal number of acid and weakly acidic refluxes, respectively. Overall, abnormal reflux parameters were detected by MII-pH monitoring in 90% of patients. Reflux events were prevalent in the upright period. On PPI therapy, acid refluxes decreased and a correspondent increase in weakly acidic refluxes was observed (median from 48.5 to 9 and from 16 to 57.5, respectively) (P < 0.001).

Conclusions: Acid refluxes, mainly in the upright period, characterize SSBO. PPI therapy transforms acid refluxes into weakly acidic refluxes.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anti-Ulcer Agents / therapeutic use*
  • Barrett Esophagus / drug therapy*
  • Barrett Esophagus / physiopathology
  • Esophageal pH Monitoring*
  • Female
  • Gastroesophageal Reflux / drug therapy*
  • Gastroesophageal Reflux / physiopathology
  • Heartburn
  • Humans
  • Hydrogen-Ion Concentration
  • Male
  • Manometry
  • Middle Aged
  • Prospective Studies
  • Proton Pump Inhibitors / therapeutic use*
  • Young Adult

Substances

  • Anti-Ulcer Agents
  • Proton Pump Inhibitors